Suspended PHASE3 INTERVENTIONAL 2-arm NCT01202630

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

A Triple-blind, Randomized, Placebo-controlled, Multi-center Study on the Effect of BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Sponsor: Bio-K Plus International Inc.

Conditions Recurrent Clostridium Difficile Infection

Interventions Lactobacillus acidophilus CL1285® and Lactobacillus casei Placebo

Updated 5 times since 2017 Last updated: Jan 14, 2016 Started: Jun 30, 2010 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

The site is unable to recruit patients.

Listed as NCT01202630, this PHASE3 trial focuses on Recurrent Clostridium Difficile Infection and remains suspended. Sponsored by Bio-K Plus International Inc., it has been updated 5 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE3
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE3
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE3
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE3
Jan 2017 — Jun 2018 [monthly]

Suspended PHASE3

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bio-K Plus International Inc.
Sprim Advanced Life Sciences

Data source: Bio-K Plus International Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Hyde Park, United States